Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α
✍ Scribed by Mariko Kobayashi; Kazuaki Chayama; Yasuji Arase; Akihito Tsubota; Satoshi Saitoh; Yoshiyuki Suzuki; Masahiro Kobayashi; Mizuho Kobayashi; Kenji Ikeda; Marie Matsuda; Hiromi Koike; Michie Hashimoto; Hiromitsu Kumada
- Publisher
- Springer Japan
- Year
- 1999
- Tongue
- English
- Weight
- 93 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0944-1174
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Alpha interferon is available worldwide as at least six dif-Alpha interferons have been used widely to treat chronic hepatitis C virus infection. These include recombinant inter-ferent products made by as many pharmaceutical companies. It is approved for human use in the European Union and the fero
We tested serial serum samples for hepatitis C virus RNA from patients undergoing treatment for chronic hepatitis C with interferon-a using an assay that combined reverse transcription and polymerase chain reaction. The subjects studied were 20 patients with chronic hepatitis who had serum antibody
Treatment of patients with chronic hepatitis C has had limited success because of relapses and nonresponse to interferon alfa therapy (currently the only established therapeutic agent). A retrospective study was done to determine the efficacy of re-treatment with interferon and the predictors of res
## Abstract A pilot study of chronic hepatitis C treatment was conducted in 14 patients (13 had chronic active hepatitis and 1 had liver cirrhosis). All patients were asymptomatic for the human immunodeficiency virus (HIV) type 1 (mean CD4 count of 584 ± 283 cells/mm^3^). Patients received 9 MU rlF